6 03, 2019

Alzheimer Drug Plus SSRI May Improve Depression/Cognition

By |2019-03-06T13:40:42-08:00March 6th, 2019|Brief Bulletins from the Field, Uncategorized, We Know Psychiatry|0 Comments

Adding the Alzheimer drug memantine (Namenda, Allergan) to treatment with a selective serotonin reuptake inhibitor may improve depressive symptoms, executive function, and other outcomes in older patients with both depression and cognitive complaints, new research suggests. The findings were presented at the American Association of Geriatric Psychiatry (AAGP) 2019. In a [...]

6 03, 2019

FDA Approves Intranasal Ketamine for Major Depressive Disorder

By |2019-03-06T08:05:04-08:00March 6th, 2019|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

The Food and Drug Administration yesterday approved an intranasal form of esketamine for treatment-resistant depression in adults who have failed at least two oral antidepressants of different classes. The spray, from Janssen Pharmaceutical (Spravato) is available in tamper-resistant prepackaged units of one, two, or three devices to deliver the prescribed doses [...]

18 01, 2019

Combination of Ketamine and Naltrexone Shows Promise for Addiction Treatments and Depression

By |2019-01-18T11:06:43-08:00January 18th, 2019|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

  A preliminary study of five patients suffering from both depression and substance abuse disorders suggest that isn’t the case. The study was published Jan. 9 in the journal JAMA Psychiatry. Substance abuse and depression are common in many patients, and efforts to treat both conditions simultaneously have had limited [...]

6 12, 2018

Study Links Increased Risk of Mental Disorders with Childhood Infections

By |2018-12-06T11:40:55-08:00December 6th, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Furthering the role of immune system disorders in the development of mental disorders, recent research links infections that children contract during their childhood with increased risk of mental disorders during childhood and adolescence. The first study of its kind shows that high temperatures, sore throats and infections during childhood can [...]

12 09, 2018

Cassipa Approved by FDA for Opioid Dependence

By |2018-09-12T15:28:07-08:00September 12th, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

A new dosage strength of buprenorphine and naloxone sublingual film was approved recently by the Food and Drug Administration. Cassipa sublingual film, made by Teva Pharmaceuticals, is a 16 mg/4 mg dosage of buprenorphine and naloxone for the maintenance treatment of opioid dependence. Buprenorphine and naloxone sublingual film also is [...]

23 08, 2018

How a Distant Epidemic Came Home to Roost: One Man’s Opioid Addiction

By |2018-09-12T14:58:24-08:00August 23rd, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

A front page New York Times story read, “Every year, thousands of people addicted to opioids show up at hospital emergency rooms in withdrawal so agonizing it leaves them moaning and agonizing on the floor.” The article then goes on to quote a heroin addict. I would have stopped reading [...]

9 08, 2018

Seven-Year Analysis on Benzodiazepine Prescribing for Children, Adolescents, and Young Adults Showed Marked Increase

By |2018-08-09T08:01:59-08:00August 9th, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Conclusions The overall increase in prevalence rates of BZD dispensations during the study period and the unexpectedly high proportion of individuals who were prescribed a BZD on a long-term basis at a young age indicate a lack of congruence with international and national guidelines. These findings highlight the need for [...]

2 08, 2018

Alzheimer’s Agent, BAN2401, Shows Promise; Trial Design Hits Snag

By |2018-08-02T07:56:18-08:00August 2nd, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

A monoclonal antibody,BAN2401, that targets soluble amyloid-beta oligomers, slowed cognitive decline by up to 47% while clearing brain amyloid in 81% of patients with mild cognitive impairment and very mild Alzheimer’s disease, according to phase 2 study results. A joint venture with Esai and Biogen, BAN2401, is among the most promising [...]

29 06, 2018

Bipolar Medication, Lamictal, Linked with Serious Immune System Reaction

By |2018-06-29T07:28:14-08:00June 29th, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

The Food and Drug Administration has issued a warning that the seizure and bipolar medication Lamictal (lamotrigine) can cause a rare but potentially life-threatening immune response. This life-threatening immune response, known as hemophagocytic lymphohistiocytosis (HLH), causes an uncontrolled immune response and can present as a persistent fever greater than 101° F. [...]

8 06, 2018

Effects of a depression-focused internet intervention in slot machine gamblers: A randomized controlled trial

By |2018-06-08T16:28:40-08:00June 8th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|0 Comments

By Lara Bücker , Julia Bierbrodt, Iver Hand, Charlotte Wittekind, and Steffen Moritz Background Problematic and pathological gambling have been linked to depression. Despite a high demand for treatment and negative financial consequences, only a small fraction of problematic and pathological gamblers seek professional help. The existing treatment gap could be narrowed by providing [...]